Evotec SE Logo

Evotec SE

EVT.DE

(0.8)
Stock Price

6,35 EUR

-8.97% ROA

-8.15% ROE

-16.95x PER

Market Cap.

2.981.657.915,00 EUR

42.68% DER

0% Yield

-11.95% NPM

Evotec SE Stock Analysis

Evotec SE Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Evotec SE Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (43%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.78x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 ROE

Negative ROE (-14.05%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-8.97%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-644) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Evotec SE Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Evotec SE Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Evotec SE Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Evotec SE Revenue
Year Revenue Growth
2001 0
2002 0 0%
2003 3.573.135 100%
2004 1.936.410 -84.52%
2005 64.115.000 96.98%
2006 67.354.000 4.81%
2007 32.885.000 -104.82%
2008 39.613.000 16.98%
2009 42.683.000 7.19%
2010 55.262.000 22.76%
2011 80.128.000 31.03%
2012 87.265.000 8.18%
2013 85.938.000 -1.54%
2014 89.496.000 3.98%
2015 127.677.000 29.9%
2016 164.507.000 22.39%
2017 257.630.000 36.15%
2018 375.405.000 31.37%
2019 446.437.000 15.91%
2020 500.924.000 10.88%
2021 618.034.000 18.95%
2022 751.448.000 17.75%
2023 785.112.000 4.29%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Evotec SE Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 9.304.000 100%
2006 30.307.000 69.3%
2007 36.938.000 17.95%
2008 42.537.000 13.16%
2009 20.947.000 -103.07%
2010 6.116.000 -242.5%
2011 8.437.000 27.51%
2012 8.340.000 -1.16%
2013 9.664.000 13.7%
2014 12.404.000 22.09%
2015 18.343.000 32.38%
2016 18.108.000 -1.3%
2017 17.614.000 -2.8%
2018 35.619.000 50.55%
2019 58.432.000 39.04%
2020 63.945.000 8.62%
2021 72.200.000 11.43%
2022 76.642.000 5.8%
2023 70.012.000 -9.47%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Evotec SE General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 15.540.000 100%
2006 18.576.000 16.34%
2007 17.806.000 -4.32%
2008 19.950.000 10.75%
2009 16.695.000 -19.5%
2010 15.956.000 -4.63%
2011 15.760.000 -1.24%
2012 16.301.000 3.32%
2013 16.597.000 1.78%
2014 17.990.000 7.74%
2015 25.166.000 28.51%
2016 27.013.000 6.84%
2017 42.383.000 36.26%
2018 57.012.000 25.66%
2019 66.546.000 14.33%
2020 77.238.000 13.84%
2021 96.023.000 19.56%
2022 142.699.000 32.71%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Evotec SE EBITDA
Year EBITDA Growth
2001 -12.738.396
2002 -23.911.923 46.73%
2003 -31.120.418 23.16%
2004 -28.121.099 -10.67%
2005 -600.000 -4586.85%
2006 -19.726.000 96.96%
2007 -36.078.000 45.32%
2008 -49.530.000 27.16%
2009 -17.088.000 -189.85%
2010 9.261.000 284.52%
2011 14.279.000 35.14%
2012 9.945.000 -43.58%
2013 13.612.000 26.94%
2014 11.186.000 -21.69%
2015 10.205.000 -9.61%
2016 49.133.000 79.23%
2017 58.352.000 15.8%
2018 94.776.000 38.43%
2019 121.651.000 22.09%
2020 98.982.000 -22.9%
2021 94.928.000 -4.27%
2022 94.154.000 -0.82%
2023 -39.004.000 341.4%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Evotec SE Gross Profit
Year Gross Profit Growth
2001 0
2002 0 0%
2003 3.573.135 100%
2004 1.936.410 -84.52%
2005 21.128.000 90.83%
2006 22.951.000 7.94%
2007 8.023.000 -186.07%
2008 17.636.000 54.51%
2009 18.421.000 4.26%
2010 24.346.000 24.34%
2011 34.985.000 30.41%
2012 31.023.000 -12.77%
2013 31.223.000 0.64%
2014 29.378.000 -6.28%
2015 37.987.000 22.66%
2016 58.554.000 35.12%
2017 82.568.000 29.08%
2018 112.016.000 26.29%
2019 132.891.000 15.71%
2020 125.743.000 -5.68%
2021 151.543.000 17.02%
2022 174.065.000 12.94%
2023 151.296.000 -15.05%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Evotec SE Net Profit
Year Net Profit Growth
2001 -12.766.494
2002 -23.897.629 46.58%
2003 -33.247.624 28.12%
2004 -29.463.677 -12.84%
2005 -33.583.000 12.27%
2006 -32.468.000 -3.43%
2007 -11.156.000 -191.04%
2008 -78.287.000 85.75%
2009 -45.497.000 -72.07%
2010 3.260.000 1495.61%
2011 6.749.000 51.7%
2012 2.478.000 -172.36%
2013 -25.433.000 109.74%
2014 -6.978.000 -264.47%
2015 16.516.000 142.25%
2016 27.530.000 40.01%
2017 24.257.000 -13.49%
2018 84.172.000 71.18%
2019 38.072.000 -121.09%
2020 6.252.000 -508.96%
2021 215.510.000 97.1%
2022 -175.655.000 222.69%
2023 -155.820.000 -12.73%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Evotec SE Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -41
2002 -40 -2.56%
2003 -37 -5.41%
2004 -1 -3600%
2005 -1 0%
2006 0 0%
2007 0 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 0 0%
2020 0 0%
2021 1 100%
2022 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Evotec SE Free Cashflow
Year Free Cashflow Growth
2003 -14.021.776
2004 -18.598.388 24.61%
2005 -6.281.000 -196.11%
2006 -11.781.000 46.69%
2007 -36.021.000 67.29%
2008 -44.792.000 19.58%
2009 -24.066.000 -86.12%
2010 -1.534.000 -1468.84%
2011 2.007.000 176.43%
2012 1.782.000 -12.63%
2013 1.467.000 -21.47%
2014 -9.079.000 116.16%
2015 4.155.000 318.51%
2016 57.211.000 92.74%
2017 -6.759.000 946.44%
2018 128.373.000 105.27%
2019 10.311.000 -1145.01%
2020 -54.351.000 118.97%
2021 3.294.000 1750%
2022 21.752.000 84.86%
2023 -25.163.000 186.44%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Evotec SE Operating Cashflow
Year Operating Cashflow Growth
2003 -14.021.776
2004 -18.598.388 24.61%
2005 -2.137.000 -770.3%
2006 -9.225.000 76.83%
2007 -31.672.000 70.87%
2008 -41.278.000 23.27%
2009 -21.853.000 -88.89%
2010 899.000 2530.81%
2011 10.146.000 91.14%
2012 11.957.000 15.15%
2013 6.657.000 -79.62%
2014 -3.797.000 275.32%
2015 15.651.000 124.26%
2016 67.360.000 76.77%
2017 10.828.000 -522.09%
2018 156.240.000 93.07%
2019 42.216.000 -270.1%
2020 44.721.000 5.6%
2021 122.237.000 63.41%
2022 203.106.000 39.82%
2023 20.759.000 -878.4%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Evotec SE Capital Expenditure
Year Capital Expenditure Growth
2003 0
2004 0 0%
2005 4.144.000 100%
2006 2.556.000 -62.13%
2007 4.349.000 41.23%
2008 3.514.000 -23.76%
2009 2.213.000 -58.79%
2010 2.433.000 9.04%
2011 8.139.000 70.11%
2012 10.175.000 20.01%
2013 5.190.000 -96.05%
2014 5.282.000 1.74%
2015 11.496.000 54.05%
2016 10.149.000 -13.27%
2017 17.587.000 42.29%
2018 27.867.000 36.89%
2019 31.905.000 12.66%
2020 99.072.000 67.8%
2021 118.943.000 16.71%
2022 181.354.000 34.41%
2023 45.922.000 -294.92%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Evotec SE Equity
Year Equity Growth
2001 36.204.513
2002 18.702.989 -93.58%
2003 -62.372.645 129.99%
2004 61.062.200 202.15%
2005 148.669.000 58.93%
2006 137.182.000 -8.37%
2007 170.553.000 19.57%
2008 149.859.000 -13.81%
2009 110.874.000 -35.16%
2010 132.161.000 16.11%
2011 147.245.000 10.24%
2012 152.547.000 3.48%
2013 158.967.000 4.04%
2014 158.383.000 -0.37%
2015 185.502.000 14.62%
2016 213.035.000 12.92%
2017 330.755.000 35.59%
2018 424.880.000 22.15%
2019 477.029.000 10.93%
2020 722.846.000 34.01%
2021 1.377.685.000 47.53%
2022 1.187.184.000 -16.05%
2023 1.140.819.000 -4.06%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Evotec SE Assets
Year Assets Growth
2001 36.204.513
2002 18.702.989 -93.58%
2003 41.727.071 55.18%
2004 70.909.490 41.15%
2005 186.111.000 61.9%
2006 205.526.000 9.45%
2007 207.878.000 1.13%
2008 182.900.000 -13.66%
2009 146.599.000 -24.76%
2010 191.859.000 23.59%
2011 218.213.000 12.08%
2012 225.427.000 3.2%
2013 227.380.000 0.86%
2014 224.600.000 -1.24%
2015 288.538.000 22.16%
2016 351.366.000 17.88%
2017 667.268.000 47.34%
2018 771.883.000 13.55%
2019 1.180.912.000 34.64%
2020 1.462.895.000 19.28%
2021 2.235.161.000 34.55%
2022 2.257.247.000 0.98%
2023 2.254.509.000 -0.12%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Evotec SE Liabilities
Year Liabilities Growth
2001 0
2002 0 0%
2003 5.697.165 100%
2004 9.182.641 37.96%
2005 37.442.000 75.48%
2006 68.350.000 45.22%
2007 37.325.000 -83.12%
2008 33.041.000 -12.97%
2009 35.112.000 5.9%
2010 59.222.000 40.71%
2011 70.968.000 16.55%
2012 72.880.000 2.62%
2013 68.413.000 -6.53%
2014 66.217.000 -3.32%
2015 101.444.000 34.73%
2016 137.430.000 26.18%
2017 335.521.000 59.04%
2018 347.003.000 3.31%
2019 703.883.000 50.7%
2020 740.049.000 4.89%
2021 857.476.000 13.69%
2022 1.070.063.000 19.87%
2023 1.113.690.000 3.92%

Evotec SE Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.25
Net Income per Share
-0.99
Price to Earning Ratio
-16.95x
Price To Sales Ratio
3.97x
POCF Ratio
14.66
PFCF Ratio
137.08
Price to Book Ratio
2.51
EV to Sales
4.09
EV Over EBITDA
40.81
EV to Operating CashFlow
15.13
EV to FreeCashFlow
141.28
Earnings Yield
-0.06
FreeCashFlow Yield
0.01
Market Cap
2,98 Bil.
Enterprise Value
3,07 Bil.
Graham Number
12.26
Graham NetNet
-0.75

Income Statement Metrics

Net Income per Share
-0.99
Income Quality
-1.16
ROE
-0.14
Return On Assets
-0.04
Return On Capital Employed
-0
Net Income per EBT
1.18
EBT Per Ebit
174.26
Ebit per Revenue
-0
Effective Tax Rate
-0.18

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.27
Operating Profit Margin
-0
Pretax Profit Margin
-0.1
Net Profit Margin
-0.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.15
Free CashFlow per Share
0.12
Capex to Operating CashFlow
-0.89
Capex to Revenue
-0.24
Capex to Depreciation
0
Return on Invested Capital
0.09
Return on Tangible Assets
-0.09
Days Sales Outstanding
124.7
Days Payables Outstanding
61.49
Days of Inventory on Hand
18.85
Receivables Turnover
2.93
Payables Turnover
5.94
Inventory Turnover
19.36
Capex per Share
-1.03

Balance Sheet

Cash per Share
4,13
Book Value per Share
6,72
Tangible Book Value per Share
5.03
Shareholders Equity per Share
6.72
Interest Debt per Share
2.94
Debt to Equity
0.43
Debt to Assets
0.22
Net Debt to EBITDA
1.22
Current Ratio
3.18
Tangible Asset Value
0,89 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.43
Working Capital
0,74 Bil.
Intangibles to Total Assets
0.13
Average Receivables
0,22 Bil.
Average Payables
0,09 Bil.
Average Inventory
30349500
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Evotec SE Dividends
Year Dividends Growth

Evotec SE Profile

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

CEO
Dr. Werner Lanthaler M.B.A.,
Employee
4.952
Address
Essener Bogen 7
Hamburg, 22419

Evotec SE Executives & BODs

Evotec SE Executives & BODs
# Name Age
1 Dr. Matthias Evers Ph.D.
Chief Bus. Officer & Member of Management Board
70
2 Dr. Cord Dohrmann Ph.D.
Chief Scientific Officer & Member of Management Board
70
3 Dr. Matthias Evers
Chief Bus. Officer & Member of Management Board
70
4 Dr. Christian Dargel
EVice President Global Head of Legal & Compliance
70
5 Dr. Ian M. Hunneyball
Senior Vice President of Programme Management & Clinical Operations
70
6 Gabriele Hansen
Senior Vice President & Head of Global Corporation Communications & Marketing
70
7 Mr. Volker Braun
Senior Vice President and Global Head of Investor Relations & ESG
70
8 Ms. Monika Conradt
Global Head of HR
70
9 Ms. Laetitia Rouxel
Chief Financial Officer & Member of Management Board
70
10 Dr. Craig Johnstone Ph.D.
Chief Operating Officer & Member of Management Board
70
11 Mr. Enno Spillner
Chief Financial Officer & Member of Management Board
70
12 Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
Chairman of Management Board & Chief Executive Officer
70
13 Dr. Craig Johnstone
Chief Operating Officer & Member of Management Board
70
14 Ms. Anja Bosler
Principal Accounting Officer and Senior Vice President of Group Accounting
70

Evotec SE Competitors

MorphoSys AG Logo
MorphoSys AG

MOR.DE

(0.8)
AIXTRON SE Logo
AIXTRON SE

AIXA.DE

(3.8)
Carl Zeiss Meditec AG Logo
Carl Zeiss Meditec AG

AFX.DE

(3.0)
Bechtle AG Logo
Bechtle AG

BC8.DE

(2.8)
Qiagen N.V. Logo
Qiagen N.V.

QIA.DE

(1.5)